Inventor

BONVINI EZIO

US42 patents

⚠️ This page may combine multiple inventors who share the name “BONVINI EZIO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

BONVINI EZIO

MACROGENICS INC

Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof

PD-1-binding molecules and methods of use thereof

Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof

Multi-chain polypeptide-containing tri-specific binding molecules

HER2/neu-specific antibodies and methods of using same

HER2/neu-specific antibodies and methods of using the same

PD-1-binding molecules and methods of use thereof

HER2/neu-specific antibodies and methods of using same

Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens

HER2/neu-specific antibodies and methods of using same

Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof

LAG-3-binding molecules and methods of use thereof

Variant CD3-binding domains and their use in combination therapies for the treatment of disease

Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof

Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof

LAG-3-binding molecules and methods of use thereof

Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof

Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof

Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof

Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof

Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof

Multi-chain polypeptide-containing tri-specific binding molecules

Tri-specific binding molecules that specifically bind to multiple cancer antigens

ADAM9-binding molecules, and methods of use thereof

Combination therapy for the treatment of cancer

Combination therapy for the treatment of cancer

HER2/neu-specific antibodies and methods of using same

Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof

Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4

Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof

PD-1-binding molecules and methods of use thereof

CD137 binding molecules and uses thereof

B7-H3 directed antibody drug conjugates

B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof

Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof

KOENIG SCOTT

FcγRIIB specific antibodies and methods of use thereof

FcγRIIB specific antibodies and methods of use thereof

FcγRIIB specific antibodies and methods of use thereof

Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity

Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity

JOHNSON LESLIE S

HER2/neu-specific antibodies and methods of using same

BONVINI EZIO

Deimmunized serum-binding domains and their use in extending serum half-life